Benralizumab‐resistant mucus plugs in severe asthma complicated by eosinophilic chronic rhinosinusitis
It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co-morbidities. If the initial biologic is insufficiently effective, it is worth considering an alternative biologic.
Authors
- Masamitsu Hamakawa (ORCID: https://orcid.org/0009-0002-4635-4034)
- Tadashi Ishida (ORCID: https://orcid.org/0000-0001-9628-9125)
Institutions
- Kurashiki Central Hospital (JP)
Publication Details
- Journal
- Respirology Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/rcr2.70009
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd